The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more ...

AHA urges HHS to block Novo Nordisk's 340B data demand, citing legal and cost concerns for safety-net hospitals and covered entities.

AbbVie loses bid to block Tennessee 340B law as federal court upholds state statute limiting drugmaker restrictions on contract pharmacies.

The 340B Drug Pricing Program (the Program) has long been a cornerstone for healthcare providers seeking to deliver affordable care to underserved communities. However, as the regulatory and ...

A new Ohio bill won't expand the 340B program, but it will protect patients' ability to fill prescriptions at their pharmacy of choice.

The drug discount program is under scrutiny on a variety of fronts ...

A federal appeals court has revived a proposed class action accusing four major drugmakers of conspiring to restrict a government-mandated drug discount program, allegedly driving up costs for ...

Contract pharmacies began as a pragmatic response to assist low-resourced clinics and hospitals that did not have an in-house pharmacy. Many of the program’s earliest participants—Federally Qualified ...

The 340B Drug Pricing Program entitles participating hospitals and clinics (called covered entities) to purchase outpatient drugs at a substantial discount from manufacturers. Covered entities either ...

The rapid expansion of the federal 340B drug pricing program is significantly affecting Medicaid budgets, particularly in states where managed care plans oversee prescription drug benefits. New ...

Every July, the Centers for Medicare & Medicaid Services (CMS) publishes two proposed rules relating to how it plans to administer the Medicare Part B program for the next calendar year: the physician ...

The 340B drug discount program has followed a familiar health policy trajectory. An intervention that was supposed to ease cost pressures, it instead is producing cascading unintended consequences ...